Wyeth infant formula recall
This article was originally published in The Tan Sheet
Executive Summary
Voluntary recall of approximately 1.5 mil. cans of store brand powdered milk- and soy-based infant formula produced at firm's Georgia, Vt. manufacturing facility due to potential contamination with "low levels" of Enterobacter sakazakii bacteria, firm says Nov. 1. Ten recalled brands, including CVS, Parent's Choice, can be identified by expiration date between July 28, 2005 and Sept. 28, 2005 marked on bottom of can; consumers can return product to place of purchase for refund. Wyeth notes "there have been no reports of illness" from ingestion of formula; bacteria has been associated with rare cases of sepsis, meningitis and severe intestinal infection in newborn infants...
You may also be interested in...
Food Advisory Committee
Assessment, evaluation of E. sakazakii contamination of powdered infant formula will be discussed at FAC meeting March 18-19, HHS announces in Feb. 20 Federal Register. Open to the public, the meeting also will address contamination risk reduction strategies based on available data, as well as research questions and priorities. Written comments are due March 3; meeting will take place at 4700 River Rd., Riverdale, Md. Wyeth recalled roughly 1.5 mil. cans of store brand powdered milk- and soy-based formula last year due to possibility of "low level" contamination with the bacteria (1"The Tan Sheet" Nov. 4, 2002, In Brief)...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.